Blueprint Medicines (NASDAQ:BPMC) Given “Peer Perform” Rating at Wolfe Research

Wolfe Research reissued their peer perform rating on shares of Blueprint Medicines (NASDAQ:BPMC) in a research note issued to investors on Tuesday morning,Benzinga reports.

Other equities research analysts have also issued reports about the stock. Wedbush reaffirmed a “neutral” rating and set a $129.00 price target (up from $128.00) on shares of Blueprint Medicines in a report on Monday. Stephens reaffirmed an “equal weight” rating and set a $135.00 price target (down from $150.00) on shares of Blueprint Medicines in a report on Tuesday. Wall Street Zen raised shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a report on Friday, May 2nd. HC Wainwright reaffirmed a “buy” rating and set a $135.00 price target on shares of Blueprint Medicines in a report on Friday, May 2nd. Finally, Scotiabank lowered shares of Blueprint Medicines from a “strong-buy” rating to a “hold” rating and set a $135.00 price target on the stock. in a report on Monday. Twelve research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Blueprint Medicines currently has an average rating of “Hold” and a consensus price target of $125.38.

Blueprint Medicines Price Performance

BPMC stock opened at $127.60 on Tuesday. The company has a quick ratio of 2.80, a current ratio of 2.85 and a debt-to-equity ratio of 1.15. Blueprint Medicines has a 12 month low of $73.04 and a 12 month high of $128.15. The firm has a market cap of $8.24 billion, a P/E ratio of -118.15 and a beta of 0.83. The company’s 50-day moving average price is $93.17 and its two-hundred day moving average price is $95.16.

Blueprint Medicines (NASDAQ:BPMC) last announced its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.32). The company had revenue of $149.41 million for the quarter, compared to the consensus estimate of $158.31 million. Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. During the same period last year, the firm posted $1.40 earnings per share. On average, analysts anticipate that Blueprint Medicines will post -1.28 earnings per share for the current fiscal year.

Insider Activity at Blueprint Medicines

In other Blueprint Medicines news, Director Jeffrey W. Albers sold 5,000 shares of the business’s stock in a transaction on Tuesday, May 27th. The shares were sold at an average price of $101.14, for a total transaction of $505,700.00. Following the completion of the sale, the director now owns 146,630 shares in the company, valued at approximately $14,830,158.20. The trade was a 3.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Ariel Hurley sold 2,752 shares of the business’s stock in a transaction on Monday, May 5th. The shares were sold at an average price of $103.13, for a total transaction of $283,813.76. Following the sale, the insider now owns 16,944 shares of the company’s stock, valued at $1,747,434.72. This trade represents a 13.97% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,574 shares of company stock worth $1,465,528 in the last quarter. Company insiders own 4.21% of the company’s stock.

Institutional Trading of Blueprint Medicines

Hedge funds and other institutional investors have recently bought and sold shares of the business. Headlands Technologies LLC bought a new stake in Blueprint Medicines during the 4th quarter valued at $65,000. Thematics Asset Management bought a new stake in Blueprint Medicines during the 4th quarter valued at $72,000. Covestor Ltd grew its stake in shares of Blueprint Medicines by 62.7% in the 4th quarter. Covestor Ltd now owns 973 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 375 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Blueprint Medicines in the 1st quarter worth $87,000. Finally, Asset Management One Co. Ltd. bought a new stake in shares of Blueprint Medicines in the 4th quarter worth $88,000.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.